Business Wire

WORKATO

3.2.2023 16:16:37 CET | Business Wire | Press release

Share
Workato Named a Leader in the 2023 Gartner® Magic Quadrant™ for iPaaS

Workato, the leading enterprise automation and integration platform, announced today that it has again been recognised as a Leader in the 2023 Gartner® Magic Quadrant™ for Integration Platform as a Service. Workato has been named a Leader all five years it has participated in the Gartner® Magic Quadrant™ for iPaaS. The report evaluated 16 total software vendors and placed Workato in the Leaders quadrant for its ability to execute, and completeness of vision. For us, Workato’s position within the Leaders quadrant signals one of the best positionings of a modern iPaaS to date.

The Workato platform enables enterprises to automate their business processes across the entire organization by integrating their applications, data, and experiences. Designed with best-in-class security and governance, scalability, performance, and availability, Workato’s low-code, no-code platform makes it easy for IT and business teams to integrate their applications and automate their processes, drawing from thousands of automation “recipes” built by the Workato community. With Workato’s democratized approach to automation and integration, business technologists are empowered to fuel their organization’s digital transformation.

“We founded Workato with the mission to rethink integration. This year’s Magic Quadrant for iPaaS highlights a significant change in the market's future and we are honored to be recognized as a Leader,” said Vijay Tella, Co-founder, and CEO of Workato. “Automation and integration is one of the top priorities for C-Suite, with a growing backlog of these projects across the enterprise. Workato’s breadth of features paired with strong security and governance capabilities enable organizations of any size to democratize complex projects enabling both IT and business technologist teams to drive business outcomes at scale across their enterprise. It's exciting to see Workato with the highest customer experience ratings on Gartner Peer Review citing Workato's ease of use and high quality of support. We are proud that Workato's mission and execution have pushed us to the forefront over the last 12 months."

In addition to being named a Leader in the report, Workato has the highest overall rating, 4.9 out of 5, on Gartner Peer InsightsTM and the most 5-star reviews, 234 out of 264, as of January 25, 2023. Customers that have shared their experience of using Workato in the past year include:

“With Workato, we are able to seamlessly integrate the data in our HCM system with other applications to accelerate and improve the hiring and onboarding process and help ensure our new hires are successful in their roles,” said Arlen Thurber, Senior Business & Systems Engineer at DataStax. “We’ve automated 6,500 emails for a time savings of 99.9%. Workato made it easy to integrate our people data so we could automate a time-consuming and distracting process without compromising our high standards for management and security.”

Gartner Magic Quadrant™ research methodology provides a graphical competitive positioning of four types of technology providers in fast-growing markets: Leaders, Visionaries, Niche Players and Challengers. According to the 2023 report for iPaaS, Workato is recognized in the Leader quadrant, which is classified as having executed well against its current vision of today and being well positioned for tomorrow.

This announcement follows a year of milestones for the company which includes being recognized as a CNBC Disruptor, launching the first Automate World Tour, and releasing two industry reports, The Work Automation Index and the vendor-neutral State of Business Technology Report. In addition to being named in Gartner, Workato also secured placement on this year’s Deloitte Technology Fast 500 and the Forbes Cloud 100 rankings.

Access a complimentary copy of the Gartner report and learn more about Workato at https://www.workato.com.

*Source: Gartner, Magic Quadrant for Integration Platform as a Service, Worldwide, Keith Guttridge, Andrew Comes, Saikat Ray, et al., January 24, 2023.

Gartner does not endorse any vendor, product, or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designations. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

GARTNER is a registered trademark and service mark, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

About Workato

As a leader in Enterprise Automation, Workato enables IT and business teams to drive business outcomes at scale by automating their processes and integrating their data, apps, and user experience across their entire organization with best-in-class security and governance. Further, Workato can also be embedded by SaaS providers to address their product integration needs. Over 17,000 of the world's top brands, like Payless, Broadcom, Helen of Troy, Logitech, Atlassian, Autodesk, Hubspot, and Toast, choose Workato to accelerate their business transformation initiatives. Headquartered in Mountain View, Calif., Workato is backed by Altimeter Capital, Battery Ventures, Insight Venture Partners, Tiger Global, and Redpoint Ventures. For more information, visit workato.com or connect with us on social media:

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230203005235/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye